- Home
- TMHC vs GH Comparison
TMHC vs GH Comparison
Compare TMHC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMHC
- GH
- Stock Information
- Founded
- TMHC 1936
- GH 2011
- Country
- TMHC United States
- GH United States
- Employees
- TMHC N/A
- GH N/A
- Industry
- TMHC Homebuilding
- GH Medical Specialities
- Sector
- TMHC Consumer Discretionary
- GH Health Care
- Exchange
- TMHC Nasdaq
- GH Nasdaq
- Market Cap
- TMHC 5.6B
- GH 4.9B
- IPO Year
- TMHC 2013
- GH 2018
- Fundamental
- Price
- TMHC $58.76
- GH $49.14
- Analyst Decision
- TMHC Buy
- GH Strong Buy
- Analyst Count
- TMHC 8
- GH 20
- Target Price
- TMHC $75.63
- GH $54.35
- AVG Volume (30 Days)
- TMHC 901.6K
- GH 2.2M
- Earning Date
- TMHC 07-23-2025
- GH 08-06-2025
- Dividend Yield
- TMHC N/A
- GH N/A
- EPS Growth
- TMHC 23.02
- GH N/A
- EPS
- TMHC 8.60
- GH N/A
- Revenue
- TMHC $8,364,403,000.00
- GH $773,996,000.00
- Revenue This Year
- TMHC N/A
- GH $23.14
- Revenue Next Year
- TMHC $0.95
- GH $21.42
- P/E Ratio
- TMHC $6.77
- GH N/A
- Revenue Growth
- TMHC 12.19
- GH 28.20
- 52 Week Low
- TMHC $51.90
- GH $20.14
- 52 Week High
- TMHC $75.49
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- TMHC 53.02
- GH 62.17
- Support Level
- TMHC $56.68
- GH $48.00
- Resistance Level
- TMHC $59.69
- GH $51.71
- Average True Range (ATR)
- TMHC 1.64
- GH 2.67
- MACD
- TMHC 0.07
- GH 0.39
- Stochastic Oscillator
- TMHC 64.31
- GH 78.60
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.